Jeremy David Block.
B.Sc. (Eng.); M.Sc. (Micro/Stats); D. Pharm.; Ph.D. (Neuro - IAGIM Research Unit)
Part Five / - 2019/7. - Total Parts: 20 - Pages 110 and growing)

ALTERNATIVE MORE ADVANCED MS Article - www.LocumUSA.com ; Ref: "Article of the Month"
Prof. J. D. Block - Neuro-Immuno-Epidemiologist (N.I.E.)

Background:
Prof. J. D. Block served for the duration of the development of COP 1 as a senior medical/pharmaceutical researcher and part of the Teva COP 1 innovative research team in the early nineties that rapidly developed Teva's first MS immuno-modulating drug Glatiramer Acetate (CopaxoneTM). As Chief Scientist as well as Teva's Group Scientific Research Auditor, and by touching each and every part of the Teva's organization and the overall scientific team, Teva rapidly attained New Drug Registration with the FDA under J. D. Block scientific and technical guidance and regulatory department training, GRP, GMP GLP, SOPs, Analytical audits and global organization overview (from early active material synthesis to manufacture and then final freeze dried packaging).

Epidemiology Note*
ISRAEL Israeli Jews have a prevalence of up to 62 per 100,000, but Christians (35 per 100,000), Moslem Arabs (15), Druze (11), and Bedouins (17) have lower rates (Alter et al 2006). Genetically similar immigrants have half the rate of native-born Jews, suggesting an environmental factor. Other groups also have a significantly lower incidence of multiple sclerosis (Caucasians Hispanics Latino's black African Americans, Asians African Natives, Inuits, SWA bushman, and Romani Gypsies (almost zero)).

Top of Page
\| Home \| Overview \| Contact Us \| IAGIM Online \| New Journals \|
\| Worldwide Web sites \| Partnerships \| Drug ID List \| DOPs \| SOP Index \| SI Assays \| Site Map \|
\| Shipping \| By FastTrack \| Data Protection \| \| Fast Service \| Press Reports \| Copyright LIG © 2019/17 Locum International Inc. All Rights Reserved. Read our Terms & Conditions of Use - \| TEL MESSAGE: 24 x 7 - \| - - +1-561-865-6147- \|





	SEARCH	[Advanced Search]
IAGIM - Drug Development Association

IAGIM DRUG and MEDICAL RESEARCH
THE INTERNATIONAL GLIMER I, II & III MS STUDY (Ongoing 2010 - 2025 - Fifteen Year GLIMER I, II and III MS Research Project - Extended 2019)
Prof. J. D. Block - Neuro-Immuno Epidemiologist (N.I.E.) Chief Scientist IAGIM Institute and CEO LIGroup

ALTERNATIVE MORE ADVANCED MS Article - www.LocumUSA.com ; Ref: "Article of the Month" Prof. J. D. Block - Neuro-Immuno-Epidemiologist (N.I.E.)


Jeremy David Block. B.Sc. (Eng.); M.Sc. (Micro/Stats); D. Pharm.; Ph.D. (Neuro - IAGIM Research Unit) Part Five / - 2019/7. - Total Parts: 20 - Pages 110 and growing) ALTERNATIVE MORE ADVANCED MS Article - www.LocumUSA.com ; Ref: "Article of the Month" Prof. J. D. Block - Neuro-Immuno-Epidemiologist (N.I.E.) Background: Prof. J. D. Block served for the duration of the development of COP 1 as a senior medical/pharmaceutical researcher and part of the Teva COP 1 innovative research team in the early nineties that rapidly developed Teva's first MS immuno-modulating drug Glatiramer Acetate (CopaxoneTM). As Chief Scientist as well as Teva's Group Scientific Research Auditor, and by touching each and every part of the Teva's organization and the overall scientific team, Teva rapidly attained New Drug Registration with the FDA under J. D. Block scientific and technical guidance and regulatory department training, GRP, GMP GLP, SOPs, Analytical audits and global organization overview (from early active material synthesis to manufacture and then final freeze dried packaging). Epidemiology Note* ISRAEL Israeli Jews have a prevalence of up to 62 per 100,000, but Christians (35 per 100,000), Moslem Arabs (15), Druze (11), and Bedouins (17) have lower rates (Alter et al 2006). Genetically similar immigrants have half the rate of native-born Jews, suggesting an environmental factor. Other groups also have a significantly lower incidence of multiple sclerosis (Caucasians Hispanics Latino's black African Americans, Asians African Natives, Inuits, SWA bushman, and Romani Gypsies (almost zero)).